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Determination of the avidity of specific IgG antibodies has become a generally accepted
diagnostic aid for dating Toxoplasma infection. In this study, the Labsystems, VIDAS and
EUROIMMUN Toxoplasma IgG avidity assays were compared on a series of 133 Toxoplasma
IgG- and IgM-positive sera from symptomatic patients (n528), from pregnant (n543) and non-
pregnant (n526) women, and on 18 IgG-positive and IgM-negative sera from chronically infected
patients. The results showed excellent concordance between the Labsystems and VIDAS tests in
both the IgM-positive (r50.82, k50.771) and IgM-negative (k50.609) sera, whilst the agreement
of the EUROIMMUN assay with both the Labsystems and VIDAS tests in the IgM-positive sera
was moderate (k50.575 and k50.525, respectively) and in the IgM-negative sera was poor
(k50.000). Analysis of the kinetics of the maturation of avidity in 13 patients in whom follow-up
sera were available showed that, despite a general trend of maturation, in two patients the avidity
did not become high during 6 and 11 months of follow-up. In view of the clinical setting, in the
symptomatic patients, despite one case of complete discrepancy and five cases of partial
discrepancy, the Labsystems and VIDAS tests were in almost perfect agreement (k50.812),
whilst the agreement in pregnant and non-pregnant women was substantial (k50.754 and
k50.708, respectively). In conclusion, the Labsystems and VIDAS tests are equally reliable for the
measurement of Toxoplasma IgG avidity; the choice of test should depend on the laboratory set-
up. The EUROIMMUN test may be an acceptable alternative in resource-limited settings, but
should be used prudently.
INTRODUCTION
The discovery that the avidity of specific antibodies as a
measure of their affinity for the antigen increases over time
(Brown et al., 1984) has resulted in its clinical application
for the diagnosis of a number of infectious diseases
including viral infections and toxoplasmosis (Hedman &
Seppälä, 1988; Hedman et al., 1989, 1993). In less than two
decades, determination of the avidity of specific antibodies
has become a standard supplementary tool for the dating of
Toxoplasma infection. In symptomatic infection, IgG
avidity is helpful in the differential diagnosis of lympha-
denopathy (Montoya et al., 2004); however, its major use
has been in the discrimination between recent and chronic
asymptomatic infection in pregnancy (Lappalainen et al.,
1993; Jenum et al., 1997; Logar et al., 1999; Liesenfeld et al.,
2001). Because the clinical management of pregnancy
depends on knowledge of the time of infection versus
conception, determination of specific IgG avidity is
particularly important in the case of detection of specific
IgM antibodies, which may be present for a prolonged
period of time (Bobić et al., 1991; Montoya & Remington,
1995). In such cases, a consensus has been reached on the
value of avidity to help rule out infections acquired in the
last few months (Liesenfeld et al., 2001; Remington et al.,
2004; Petersen et al., 2005; Petersen, 2007; Flori et al.,
2008).
Due to the technical ease with which the specific IgG
avidity can be determined (by use of a dissociating agent
such as urea to break up weak antigen–antibody associa-
tions), many laboratories developed in-house assays for its
measurement, which was later followed by the introduction
of a number of commercial tests. These tests differ in the
antigen source and preparation, and in the use of serial or a
single pre-determined serum dilution, or one containing a
specified amount of Toxoplasma IgG antibodies, as well as
in the calculation and interpretation of results. Such
variables may influence performance. However, few studies
comparing commercial tests have been published to date
(Barberi et al., 2001; Alvarado-Esquivel et al., 2002;
Horvath et al., 2005; Petersen et al., 2005; Soula et al.,
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2007). We thus performed a study to compare three such
tests.
METHODS
Study design. The performance of three commercial assays for the
measurement of the avidity of Toxoplasma-specific IgG antibodies
was examined in a total of 151 serum samples (133 sera positive for
both specific IgG and IgM, and 18 IgG-positive, IgM-negative sera.
In addition, the kinetics of IgG avidity maturation was analysed in a
subgroup of 13 patients in which follow-up sera were available.
Finally, the significance of the avidity results was analysed in the
clinical context.
Patients and sera. The study series comprised a panel of 151
Toxoplasma IgG-positive serum samples obtained from 115 immu-
nocompetent patients examined for toxoplasmosis at the National
Reference Laboratory for Toxoplasmosis at the Institute for Medical
Research, University of Belgrade, Serbia, between May 2004 and
December 2006.
Of the 151 sera, 133 from 97 patients were positive for Toxoplasma
IgM, whilst the 18 Toxoplasma IgM-negative sera originated from 18
randomly selected patients with chronic infection. Among the IgM-
positive patients, 38 follow-up serum samples were available from 13
patients with a low or borderline avidity in their first sample; 33 of
these (two samples in eight patients, three samples in four patients
and five samples in one patient) were included in the study of the
comparison of the tests. An additional five follow-up samples (from
three patients), which arrived after the end of the comparative study,
were analysed only by VIDAS.
According to the clinical setting, the IgM-positive patients comprised
28 with clinical infection (lymphadenopathy), whilst 69 were
asymptomatic women tested for obstetric reasons. Of the latter, 43
women were pregnant at the time of testing and the remaining 26
were examined for history of miscarriage, premature delivery, etc., or
as a pre-pregnancy control.
The study was approved by a local (Institute for Medical Research)
Ethics Committee.
Serological tests
Detection of specific IgG antibodies. Specific IgG antibodies were
detected using a high-sensitivity direct agglutination assay and the
VIDAS Toxo IgG II assay (bioMérieux). The direct agglutination
assay was performed as described by Desmonts & Remington (1980),
using formalin-fixed RH strain tachyzoites as antigen, kindly obtained
from Dr P. Thulliez (Institut de Puériculture, Paris, France). Sera
were serially diluted twofold starting from 1 : 20; the first dilution
considered positive was 1 : 40 (2 IU ml21 according to both the WHO
reference serum and a laboratory standard serum). The Toxo IgG II
assay (which uses an enzyme-linked fluorescent assay technique) was
performed on the fully automated VIDAS system. Results were
interpreted as recommended by the manufacturer, as follows: ,4 IU
ml21, negative; 4–8 IU ml21, borderline; .8 IU ml21, positive.
Detection of specific IgM antibodies. Specific IgM antibodies were
detected using the commercial IgM-immunosorbent agglutination
assay (bioMérieux) and/or the VIDAS Toxo IgM assay (bioMérieux),
as recommended by the manufacturer. For the IgM-immunosorbent
agglutination assay, results were expressed as an index on a scale of 0–
12, where 0–5 was considered negative, 6–8 was borderline and ¢9
was positive. The cut-off value for the VIDAS Toxo IgM assay was
0.55, results between 0.55 and 0.65 were considered borderline, whilst
results above 0.65 were considered positive.
Avidity assays. The avidity of the specific IgG antibodies was
measured using three commercial assays, as follows: the Toxoplasma
gondii IgG avidity enzyme immunoassay (Ani Labsystems), the
VIDAS Toxo IgG avidity assay (bioMérieux) and an ELISA adapted
for IgG avidity determination (EI 2410-9601-1 G; EUROIMMUN).
Each was performed according to the instructions of the respective
manufacturer. The avidity results for the Labsystems assay were
calculated according to the distances (in mm) between the lines
obtained by plotting the titration curves, and for the EUROIMMUN
test by calculating the ratio of the absorbance values of the sample
obtained with and without urea treatment. In contrast, the VIDAS
test is a fully automated assay where the results are produced directly
by the system software. Results were expressed as avidity percentages
(Labsystems and EUROIMMUN) or indices (VIDAS). The respective
manufacturer-recommended cut-off values with the interpretation of
the results, classified as high, low or borderline avidity, are presented
in Table 1.
Data analysis. The results of avidity tests were analysed per pair of
tests, with borderline results grouped with either the low-avidity or
the high-avidity results. Test results in this dichotomous form were
classified into two-by-two contingency tables and the overall
(observed) agreements were calculated. The concordance between
the tests was determined by Pearson’s correlation coefficient (r) and,
in addition, by k statistics; k values of 0.01–0.20 indicated slight
agreement, 0.21–0.40 fair, 0.41–0.60 moderate, 0.61–0.80 substantial
and 0.81–0.99 almost perfect agreement (Landis & Koch, 1977).
In addition, where appropriate, the results obtained in different pairs
of tests were analysed as being in agreement (low, borderline or high
in both tests), partially discrepant (low or high in one, and borderline
in the other test) or completely discrepant (low in one and high in the
other test).
RESULTS
The results of a comparative investigation of three
commercial tests for the measurement of specific IgG
Table 1. Cut-off values and result interpretation of the commercial IgG antibody avidity tests as recommended by the respective
manufacturer
Test Low avidity Borderline avidity High avidity Interpretation for high avidity
Ani Labsystems ,15 % 15–30 % .30 % Excludes infection in the last 3 months
EUROIMMUN ,40 % 40–60 % .60 % Unspecified
VIDAS* ,0.2 0.2–0.3 .0.3 Excludes infection in the last 4 months
*Corresponds to ,20 %, ,20–30 % and .30 %.
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antibody avidity on a series of 133 sera positive for both
Toxoplasma IgG and IgM are presented in Fig. 1. All three
tests analysed per pair correlated well, with a strong
correlation between Labsystems and VIDAS tests (r50.82),
and good correlation between the EUROIMMUN and both
Labsystems and VIDAS tests (r 50.69 and 0.66, respect-
ively). Similarly, analysis of the results by k statistics
showed at least moderate agreement between all pairs of
tests (Table 2). However, whilst the EUROIMMUN assay
showed only moderate agreement with both the
Labsystems and VIDAS tests, the agreement between the
Labsystems and VIDAS tests was substantial. The agree-
ment depended somewhat on whether the borderline
values were grouped with the low- or high-avidity values.
Although all statistical calculations are presented, it should
be borne in mind that, given that interpretation of test
results is generally limited to high-avidity values ruling out
recent infections (precisely how long depends on the
particular test), grouping of borderline values with the
high-avidity values does not seem meaningful. When
borderline results were grouped with the low-avidity ones,
the EUROIMMUN test agreed similarly with both
Labsystems (k50.575) and VIDAS (k50.525) tests.
When these were analysed together with the high-avidity
results, the EUROIMMUN test agreed significantly better
with the Labsystems test (k50.648) than with the VIDAS
test (k50.496) (a finding that seems to bear no real
significance in view of the above consideration). In
contrast, the Labsystems and VIDAS tests agreed substan-
tially irrespective of the grouping (k.0.7).
To examine the agreement of the avidity tests in a situation
in which IgG avidity is expected to be high, a group of 18
specific IgM-negative sera was analysed (Table 3).
Although no low-avidity value was obtained in any of the
tests, not all samples were shown to be of high avidity.
Thus, with the EUROIMMUN test, there were nine (50 %)
borderline results, whilst the Labsystems and VIDAS tests
gave four (22 %) and two (11 %) borderline results,
respectively. Accordingly, the statistical agreement of the
EUROIMMUN test with either of the latter tests was not
above the probability of chance (k50.000, P51). In
contrast, the agreement between the Labsystems and
VIDAS tests was substantial (k50.609). In two patients,
the tests were partially discrepant in that the Labsystems
result was still borderline and the VIDAS result was high,
whilst in another two patients, both tests were borderline.
These latter two patients obviously indicated delayed IgG
avidity maturation.
Having thus established the Labsystems and VIDAS tests to
be superior to the EUROIMMUN assay, only results from
these two tests were considered in further analysis. The
kinetics of IgG avidity maturation was examined in a series
of patients who presented with low or borderline avidity.
This subgroup comprised 13 patients whose initial sample
was found to be of low (seven and ten patients in the
Labsystems and VIDAS tests, respectively) or borderline
(six and three patients in the Labsystems and VIDAS tests,
Fig. 1. Correlation of Toxoplasma IgG antibody avidity levels
determined in a series of 133 IgM-positive patient sera, using the
Ani Labsystems (AniL) and VIDAS (a), Ani Labsystems and
EUROIMMUN (EImmun) (b) and VIDAS and EUROIMMUN (c)
tests. Data for individual sera fit a linear regression line as shown.
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respectively) avidity (Fig. 2). The patients were followed for
a mean of 3.38 months (range 1–12 months) for the 33
samples analysed using both the Labsystems and VIDAS
tests, and 5.46 months (range 1–14 months) when the five
later follow-up samples (analysed by VIDAS test alone)
were added. Whilst there was a general trend of
maturation, the Labsystems test showed that, of the four
patients followed for greater than 3 months, three matured
to high avidity (two from low and one from borderline)
and one matured to borderline avidity (however, this
patient was not tested beyond 4 months). On the other
hand, the VIDAS test showed that, of the seven patients
followed for more than 4 months, three patients went from
low to high avidity, one from low to borderline and two
from borderline to high, whilst one remained borderline
throughout the 6 months of follow-up. This patient, a
pregnant woman, represents an actual case of delayed
maturation of IgG antibody avidity. In addition, a similar
phenomenon was noted in one symptomatic patient (with
three samples) in whom the avidity was very low in the first
two samples taken 3 months apart, whilst the final sample
taken 8 months after the second one was borderline.
Finally, the avidity results in the IgM-positive patients were
analysed in the clinical context, i.e. according to whether
the infection was clinically manifest or not (Table 4). The
substantial agreement between the tests as shown in Table 2
varied according to the clinical setting. In the 44 samples
analysed from 28 patients with clinically manifest acute
toxoplasmosis, complete discrepancy was found in a single
sample (2.3 %). Five more samples were partially discrep-
ant (11.4 %), but the agreement was nevertheless statist-
ically almost perfect (k50.812). More importantly, of these
five, the partial discrepancy in four where the findings in
the VIDAS test were still low (in three) and borderline (in
one) whilst being borderline and high in the Labsystems
test may be attributable to a 1-month difference in
interpretation of high-avidity results (4 and 3 months,
respectively). Although there was no instance of complete
discrepancy in the asymptomatic patients, the number of
partial discrepancies amounted to 15.7 % in pregnant
women and 26.3 % in non-pregnant women. This resulted
in a statistically lower although still substantial agreement
(k50.754 and k50.708, respectively). The proportion of
low-avidity findings was highest in symptomatic patients
(47.4 %), followed by pregnant (20.9 %) and non-pregnant
(3.6 %) women. Also, when the borderline findings were
added to those of low avidity, the distribution trend
remained similar (50 vs 32.6 vs 25 % in symptomatic
patients, pregnant women and non-pregnant women,
respectively). This is not surprising as it reflects the fact
that symptomatic patients tend to be examined serologi-
cally earlier in the course of infection, whilst pregnant
Table 2. Measures of agreement of the Ani Labsystems (AniL), EUROIMMUN and VIDAS tests for determination of Toxoplasma-
specific IgG avidity on a series of 133 IgM-positive sera
L, Low avidity; B, borderline avidity; H, high avidity.
EUROIMMUN VIDAS
L+B vs H L vs B+H L+B vs H L vs B+H
VIDAS AniL VIDAS AniL AniL AniL
Overall agreement (%) 76.69 78.95 81.20 87.97 88.72 90.25
k value 0.525 0.575 0.496 0.648 0.771 0.747
P for k value 0.000 0.000 0.000 0.000 0.000 0.000
Table 3. IgG avidity findings as measured by the Ani Labsystems (AniL), EUROIMMUN and VIDAS tests on a series of 18
Toxoplasma IgM-negative sera
L, Low avidity; B, borderline avidity; H, high avidity.
Test pair k value P for k
value








L/L B/B H/H L/B B/L H/B B/H L/H H/L
EUROIMMUN/
VIDAS
0.000 1.000 0 1 8 9 (50 %) 0 0 1 8 9 (50 %) 0 0 0
EUROIMMUN/AniL 0.000 1.000 0 2 7 9 (50 %) 0 0 2 7 9 (50 %) 0 0 0
AniL/VIDAS 0.609 0.005 0 2 14 16 (88.9 %) 0 0 0 2 2 (11.1 %) 0 0 0
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women tend to be more regularly examined than those
tested for other obstetric reasons.
DISCUSSION
We compared three commercial tests for the measurement
of Toxoplasma IgG avidity, including a fully automated
assay on the VIDAS system, a well-known manual test by
Labsystems and a less well-known test by EUROIMMUN.
This latter test was included because it is readily available
and, due to its competitive price, is often used in Serbia. It
should be noted that, unlike the study of Barberi et al.
(2001), we compared the tests only per pair, in order not to
mask potential concordances between two of the three tests
as occurred in their study. An excellent concordance was
found in the results of the Labsystems and VIDAS tests in
both Toxoplasma IgM-positive and IgM-negative patients.
The strong correlation (r50.82) in the IgM-positive
patients was effectively the same as that (r50.8) in the
single previous study by Alvarado-Esquivel et al. (2002)
comparing these two tests, whereas the overall agreement
of 89 % in our larger series was better than the value of
75 % (48/64) that they obtained. Our study is the first to
date to evaluate the EUROIMMUN test. The concordance
of the EUROIMMUN test with either of the other two tests
in the Toxoplasma IgM-positive patients was weaker but
statistically good; however, this was undermined by a poor
agreement in the IgM-negative patients. Although IgM-
negative patients are not normally the target population for
IgG avidity determination, its measurement in a small
group of randomly selected patients with chronic infection
showed somewhat disappointing results, particularly with
the EUROIMMUN test; although no complete discrep-
ancies were obtained, as many as 50 % of the IgM-negative
patients had borderline avidity, compared with 22 and
11 % in the Labsystems and VIDAS tests, respectively.
These findings raise the issue of how to set the cut-off point
in different tests, as discussed previously (Flori et al., 2004,
2008; Horvath et al., 2005).
Fig. 2. Kinetics of IgG antibody avidity maturation over time in a
series of 13 patients as measured by the Ani Labsystems (a) and
the VIDAS (b) avidity assays. The cut-off points for low, borderline
and high avidity are indicated by horizontal lines.
Table 4. IgG avidity findings as measured by the Ani Labsystems and VIDAS tests on a series of 133 Toxoplasma IgM-positive sera
according to clinical setting
L, Low avidity; B, borderline avidity; H, high avidity.
Clinical setting k value P for k
value
Agreement Partial discrepancy Discrepancy
Samples (n) Total (%) Samples (n) Total (%) Samples
(n)
Total (%)
L/L B/B H/H L/B B/L H/B B/H L/H H/L
Lymphadenopathy 0.812 0.000 18 1 19 38 (86.3 %) 0 3 1 1 5 (11.4 %) 0 1 1 (2.3 %)
Pregnant women 0.754 0.000 9 5 29 43 (84.3 %) 3 1 1 3 8 (15.7 %) 0 0 0
Non-pregnant
women
0.708 0.000 1 6 21 28 (73.7 %) 4 0 1 5 10 (26.3 %) 0 0 0
Total 28 12 69 109 (81.9 %) 7 4 3 9 23 (17.3 %) 0 1 1 (0.8 %)
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According to the clinical setting, the Labsystems and
VIDAS tests showed the best agreement, as expected, in
symptomatic patients, and, in descending order but still
substantially, in pregnant and non-pregnant women.
Symptomatic patients are those in which the time of onset
of infection is known, which is a prerequisite for the
evaluation of the performance of Toxoplasma IgG avidity
tests. However, even among these patients, of the 44 serum
samples tested, there was one sample with complete
discrepancy and five samples with partial discrepancy,
explicable at least in part by the 1-month difference in the
high-avidity results interpretation. Among samples in
agreement in both tests, the proportion of low-avidity
findings in symptomatic patients was 47.4 %, and of low
together with borderline was 50 %. This reflects a delay in
presentation for serology after the onset of infection in
about half of the symptomatic patients in our series.
In the asymptomatic patients, the time of infection is
obviously unknown and such infections are discovered
only upon presentation for serology. In the specific IgM-
positive asymptomatic women in our series, the proportion
of low-avidity findings was 20.9 % in pregnant women and
only 3.6 % in non-pregnant women, and rose to 32.6 and
25 %, respectively, when borderline findings were added to
those of low avidity. This decreased proportion of
diagnosed recent infections in non-pregnant versus preg-
nant women probably reflects the fact that pregnant
women are examined more regularly than those tested
for other obstetric reasons; the latter, particularly if tested
following a pathological outcome of a previous pregnancy,
often present for serology months later, which is why, even
in cases where toxoplasmosis may have been the cause of
an adverse outcome of pregnancy, they are not tested early
enough during the course of infection. Such cases also
underline the high prevalence of specific IgM antibodies
that do not indicate infection in the immediate past.
Analysis of the kinetics of IgG avidity maturation showed
delayed maturation in 15.4 % of patients (2/13). Further
evidence for delayed maturation was presented by 11 % (2/
18) of the borderline findings in specific IgM-negative
patients obtained in both tests (two more with Labsystems,
amounting to 22 %). The persistence of low/borderline
avidity during a prolonged period of time in certain
individuals has been noted in many studies (Jenum et al.,
1997; Montoya et al., 2004; Remington et al., 2004;
Petersen et al., 2005). In a recent study of delayed
maturation of IgG avidity in pregnant women, Lefevre-
Pettazzonni et al. (2006) attributed this phenomenon to
factors including individual variations, state of pregnancy
and possibly treatment, but also to the assay system.
However, as maturation of IgG avidity is not necessarily
linear over time, it has also been considered to be
individual rather than assay-related (Petersen et al., 2005).
In conclusion, based on the results of this study, the
EUROIMMUN test may have its place, particularly in low-
resource settings, but should be used prudently. On the
other hand, the excellent concordance between the
Labsystems and VIDAS tests shows that these are equally
reliable for the measurement of Toxoplasma IgG avidity.
Any limitations of the interpretation of the avidity results
are intrinsic to the IgG avidity per se rather than to these
two tests. One advantage of the VIDAS assay is that the
results are produced by the system software, but the
appropriate apparatus is required, whereas the Labsystems
test requires no specific equipment but its performance and
calculation of the results are cumbersome and time-
consuming. Thus the choice of test should depend on the
particular laboratory framework.
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